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ABSTRACT 
Background: Accumulating evidence suggests smoking may adversely affect cancer patients’ 
outcomes.  Previous studies of smoking and survival in colon cancer have been limited by size and/or 
lack of a population-basis and results have been inconsistent. 
Aim: This large population-based cohort study investigated whether: smoking status at diagnosis is 
an independent prognostic factor for cancer-specific survival in colon cancer; and treatment 
modifies any impact of smoking. 
Methods: Colon adenocarcinomas diagnosed 1994-2012 were abstracted from the National Cancer 
Registry Ireland, and classified by smoking status at diagnosis.  Cancer-specific death rates over 5 
years were compared in current, ex- and never smokers using multivariable Cox proportional 
hazards models, and subgroup analyses by treatment (combinations of cancer-directed surgery and 
chemotherapy) conducted.  
Results: Of 18,166 colon cancers, 20% were current smokers, 23% ex-smokers and 57% never 
smokers. Compared to never smokers, current smokers had a significantly raised cancer death rate 
(multivariable hazard ratio (HR)=1.14, 95% CI: 1.07, 1.12).  There was a significant interaction 
between treatment and smoking (P=0.03). In those who had cancer-directed surgery only, but not 
other groups, current smokers had a significantly increased cancer death rate compared to never 
smokers (HR=1.21, 95% CI: 1.09, 1.34).   
Conclusions: Smoking at diagnosis is an independent prognostic factor for colon cancer. The 
limitation of the association to surgically-treated patients suggests that the underlying mechanism(s) 
may be related to surgery. While further research is needed to elucidate mechanisms, continued 
efforts to encourage smoking prevention and cessation may yield benefits in terms of improved 
survival from colon cancer. 
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INTRODUCTION 
Each year worldwide more than 750,000 new cases of colorectal cancer are diagnosed,1 around two-
thirds of which arise in the colon. There is compelling evidence for the role of a range of lifestyle 
factors - including smoking, physical activity and sedentary behaviour, weight and weight change, 
and diet - in the aetiology of colon cancer in particular.2-6  Evidence is also starting to suggest that 
lifestyle factors may be associated with survival in patients with colon cancer (see, for example, 7-9). 
Given that many lifestyle factors are potentially modifiable, greater clarity on the role of these in 
colon cancer outcomes would be of considerable public health importance. 
A 2014 report by the US Surgeon General concluded that smoking may be causally related to higher 
all-cause and cancer-specific mortality and increased risk of second primary cancers.10 A recent 
systematic review and meta-analysis of six studies of smoking and colorectal cancer survival 
estimated that, compared to never smokers, current smokers had significantly increased risk of 
death (hazard ratio=1.26, 95%CI 1.15-1.37),11 but the result was based on all-cause mortality which 
is influenced by the effects of smoking of deaths from diseases other than cancer.12 Moreover, no 
distinction was made between cancers of the colon and rectum. Four studies included in the 
systematic review reported on smoking and survival in colon cancer patients.13-16 All described 
higher risk of death, or shorter survival, among smokers (who were defined in various ways), but 
results only reached statistical significance in two of the studies.  
The majority of colon cancer patients undergo surgery and suitable patients with stage II or III 
disease may receive adjuvant chemotherapy.17 Studies suggest that short-term post-operative 
morbidity and 30-day mortality are worse in colorectal cancer patients who smoke.18,19 One small 
study of 284 colorectal cancer patients with pathologically complete resection reported a significant 
raised hazard ratio in active smokers20 but no studies appear to have investigated whether smoking 
is also associated with survival in non-surgical colon cancer patients.  Nicotine inhibits apoptosis by 
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chemotherapeutic agents in colon cancer cells21 but associations between smoking and 
chemotherapy receipt in colon cancer patients have not been examined. 
This large population-based cohort study aimed to investigate (1) whether smoking status at 
diagnosis is an independent prognostic factor for cancer-specific survival in colon cancer and (2) 
whether the association varies by whether or not patients undergo cancer-directed surgery or 
receive chemotherapy.   
METHODS 
Setting 
The study was conducted in Ireland, which has a mixed public-private healthcare system. All 
residents are entitled to care within the public system. A population-based colorectal cancer 
screening programme commenced roll-out in 2013. Prior to that, screening was not generally 
available. 
Data 
The data source was the National Cancer Registry Ireland, which aims to record all cancers newly 
diagnosed in the population usually resident in Ireland, using an active registration process. 
Completeness of registration is estimated to be at least 97%.22 Following standard protocols, trained 
tumour registration officers collect patient (e.g. date of birth, address at diagnosis), tumour (e.g. 
cancer site, date of diagnosis) and first course treatment (surgery, chemotherapy or radiotherapy 
within a year of diagnosis) details for each tumour.  The information collected includes patients’ 
smoking status at diagnosis, as recorded in their hospital records.  The Central Statistics Office 
notifies deaths to the Registry, where they are linked to registered cancers, using probabilistic 
matching methods; this allows dates and causes of death to be identified.  
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For this analysis, all cases of colon cancer diagnosed 1994-2012 (ICD10 C18, n=24,953) were 
abstracted from the Registry. Cases were excluded if they had another invasive cancer (other than 
non-melanoma skin cancer) diagnosed prior to, or following, the colon cancer (n=3,889), had a 
tumour morphology other than adenocarcinoma (n=2,842) or were identified from death certificates 
only (n=56).  Ascertainment of deaths was complete to 31/12/2012. Colon cancer-specific deaths 
were defined as those for which the underlying cause of death was coded as: cancer at the same 
diagnosis site; cancer of the same body system; cancer of another specified site; or cancer of 
unknown site.23 
In terms of treatment, each case was classified according to whether or not the patient received, 
within a year of diagnosis:  (i) cancer–directed surgery (i.e. colectomy, hemicolectomy limited 
excision with or without anastomosis, or endoscopic local excision/destruction) and (ii) at least one 
course of chemotherapy.  Age, marital status and sex were available from Registry records. Cases 
were assigned to one of five deprivation categories based on address of residence at the time of 
diagnosis. Categories ranged from least (1) to most deprived (5) and were based on a score derived 
from 2002 census variables;24 the 2002 census was used as this was closest to the middle of the 
study period. In terms of clinical variables, summary stage at diagnosis was defined according to the 
UICC classification25 and grade as well differentiated, moderately differentiated or poorly 
differentiated/undifferentiated.  Cases were categorised as being located in the proximal (ICD10 
18.0-18.5) or distal colon (18.6-18.8) or colon not otherwise specified (NOS; 18.9).   
Smoking status at diagnosis was classified as: never smoked; ex-smoker (had smoked at least once 
every month in the past but not in the previous year); and current smoker (had smoked at least once 
every month in the previous year).  For 26% of patients, smoking at diagnosis was unknown. 
Information was incomplete or missing for tumour stage (4%) and grade (12%), which are important 
prognostic factors.26,27 In total, 36% of patients had missing values for one or more of smoking 
status, stage and grade.  The missing data items in these field were populated by multiple 
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imputation by chained equations based on other available data.28,29  Multiple imputation is 
considered superior to other approaches to dealing with missing data because it produces less 
biased estimates than complete case analysis under a range of missing data scenarios and, under 
other scenarios, is more efficient than complete case analysis.30-32 Fifty datasets were generated, in 
which missing values for smoking status, grade and stage were imputed using multinomial logistic 
regression including, as covariates, socio-demographic and clinical variables, indicators of cancer-
specific death and death from any cause, and time to cancer death (or censor date) and any death 
(or censor date) (Supporting table 1).  
Statistical analysis 
The primary analysis was based on the dataset containing the imputed data. As recommended, a 
complete case analysis (considered a sensitivity analysis) was conducted for comparison.33 Our 
interest was in associations between smoking and rate of death so cancer-specific survival was the 
primary outcome and non-cancer deaths were censored (as opposed to being considered competing 
risks). For each patient, survival time was computed from the date of diagnosis to date of death, 5-
years of follow-up, or the censoring date (31st December 2012), whichever occurred first. Chi-square 
tests were used to compare patient-related and clinical characteristics of never, ex- and current 
smokers at the time of diagnosis.  Curves of cumulative incidence of cancer-specific death up to 5-
years post-diagnosis were generated by smoking status and – to aid interpretation – similar curves 
for cumulative incidence of deaths due to other causes. Unadjusted and multivariable hazard ratios 
for cancer-specific death within 5-years by smoking status were computed using Cox proportional 
hazards regression. Hazard ratio estimates from the 50 imputed datasets were combined to provide 
a single estimate with the standard error adjusted for inter- and intra-imputation variance according 
to Rubin’s rules.34 Variables for inclusion in the multivariable model were selected using a backwards 
stepwise approach; variables were retained if the Wald test P-value was <0.05.  For each covariate, a 
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test for proportionality of hazards was performed35 and, since the hazards for age and stage were 
non-proportional, these variables were fitted as strata in the model.   
Initially the analysis was done for all cases then repeated for subgroups defined by treatment. Since 
most treatments are received shortly after diagnosis, four subgroups were created by combining 
variables for receipt of cancer-directed surgery (yes/no) and receipt of chemotherapy (yes/no). The 
interaction between smoking and treatment was tested by fitting a cross-product term. Those who 
die soon after diagnosis have no possibility of undergoing treatment and this complicates 
comparisons of treated and untreated groups; how this might influence the relationship between 
smoking and survival is unclear. Therefore, we repeated this analysis using a landmark approach,36 
which involved restricting the analysis to patients who were alive at 6 months post-diagnosis (since 
almost all treatments had been delivered by 6 months; n=14,387).  
In the sensitivity analysis, we analysed the dataset which included all patients without missing data 
for smoking status, stage or grade (“complete cases”, n=11,648). We repeated the descriptive 
analyses and re-ran the final multivariable model to estimate hazard ratios by smoking status.  All 
analyses were done in Stata 11.0. 
Review of previous studies 
To set our findings in context, we searched Medline for other studies reporting some aspect of 
survival by smoking status in people with colon cancer. MeSH headings and text word searches were 
undertaken, combining terms for disease, smoking exposure, and outcome. To be eligible studies 
had to be published as full papers, in the English language, by 30th November 2016. Information on 
the study population, sample size, assessment of smoking status, smoking prevalence and hazard 
ratios for survival by smoking status was abstracted from the papers identified. 
RESULTS 
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Primary analyses: multiple imputed dataset 
The analysis included 18,166 incident colon cancers. After imputation, 57% of patients were 
classified as never smokers at diagnosis, 23% as ex-smokers and 20% as current smokers (Table 1). 
Slightly more than half of patients were male, 13% were aged under 55 at diagnosis and 35% were 
aged 75 or older. Cancer-directed surgery was received by 85% (n=15,502) and 38% (6,851) had 
chemotherapy. In terms of treatment combinations, 53% had cancer-directed surgery only, 33% had 
surgery and chemotherapy, 5% had chemotherapy only, and 10% had neither treatment.  
There were significant associations between smoking status and all of the socio-demographic and 
clinical variables (chi-square P<0.01 throughout; Table 1). A higher proportion of current smokers 
were diagnosed under 55, than ex-smokers or never smokers. The proportion of current smokers 
who lived in the most deprived areas was higher than for ex- and never smokers. 27% of current 
smokers had stage IV disease at diagnosis compared to 24% each of ex-smokers and never smokers. 
The percentage of current smokers who had cancer-directed surgery was slightly lower (82%) than 
among ex- (85%) and never smokers (86%). In contrast, chemotherapy receipt was more common 
among current smokers (41%) than ex- or never smokers (both 37%).   
During the 5-years post-diagnosis, there were 7,488 cancer specific deaths. The cumulative incidence 
of cancer-specific death was highest in the current smokers; the curves for ex-smokers and never 
smokers were almost identical (Supporting figure 1(a)). For non-cancer deaths, the cumulative 
incidence was consistently higher in current and ex-smokers than in never smokers (Supporting 
figure 1(b)). 
Univariate and multivariable hazard ratios for cancer-specific death by smoking status for all patients 
are shown in Table 2.  In the univariate analysis, smoking was a significant prognostic factor; 
compared to never smokers, current smokers had a significantly increased rate of cancer death, 
while ex-smokers did not. This pattern persisted after adjustment for socio-demographic and clinical 
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variables (sex, marital status, deprivation category, period of diagnosis, grade and tumour location). 
Compared to never smokers, the hazard ratio of current smokers was raised by 14% and this was 
statistically significant (multivariable HR=1.14, 95%CI 1.07-1.22). The hazard in ex-smokers did not 
differ from unity (HR=1.00, 95%CI 0.94-1.17).  
Table 3 shows the univariate and multivariable hazard ratios for smoking status in the four 
treatment groups. There was a significant interaction between smoking and treatment (p=0.034). A 
significant association between smoking and cancer-specific death was apparent among patients 
who had surgery only (P<0.01); in adjusted analysis, comparing to never smokers, current smokers 
had a 21% higher rate of cancer death (HR=1.21, 95%CI 1.09-1.34) while the rate in ex-smokers was 
not raised.  In the other three treatment groups, current smoking was not associated with a higher 
cancer death rate.   
In the landmark analysis, the same pattern was evident although the test for interaction was no 
longer statistically significant (P=0.118). In the surgery only group, current smokers had a 
significantly higher rate of death (HR=1.22, 95%CI 1.09-1.34; P<0.01); the estimates for current 
versus never smokers in the other treatment groups did not differ from unity (surgery & 
chemotherapy: 1.09, 95%CI 0.97-1.22; chemotherapy only: 1.01, 95%CI 0.82-1.25; neither surgery 
nor chemotherapy: 0.99, 95% CI 0.84-1.17). 
Sensitivity analyses: complete case dataset 
Supporting table 2 summarises the characteristics of the 11,648 patients in the complete case 
analysis.  The same pattern of association between smoking status and cumulative incidence of 
cancer-specific death was evident in this analysis as in the primary analysis based on the dataset 
with imputed values (data not shown). In univariate analyses current smokers had a 21% higher rate 
of cancer-specific death than never smokers; this attenuated slightly in the multivariable analysis but 
remained statistically significant (multivariable HR=1.17, 95%CI 1.08-1.26)(Supporting table 3). The 
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hazard ratio for ex-smokers was 0.99 in both univariate and multivariable analysis. There was a 
significant interaction between treatment and smoking (P<0.01) and, as in the primary analysis, the 
association between current smoking and cancer specific death was found only among cases who 
had surgery without chemotherapy (multivariable HR=1.28, 95%CI 1.14-1.43) (Supporting table 4). 
The same pattern, and a significant interaction (P<0.01), was seen in the landmark analysis (data not 
shown). 
Review of previous studies 
Eight studies of smoking and survival in colon cancer were identified, six from the USA, one from 
Canada and one from Germany (Table 4).7,13-16,37-39 Sample sizes ranged from 424 to 4,213. Studies 
varied in how, and at what time point, they assessed smoking status. The prevalence of current 
smokers ranged from 7% to 18%. Five studies reported on cancer-specific survival, and four each on 
disease-free, recurrence-related and overall survival. For cancer-specific, disease-free or recurrence-
free survival, all eight studies reported an increased hazard for current versus never- or non-
smokers, but this only reached statistical significance in four studies. 
DISCUSSION 
In this population-based cohort study - which is, by far, the largest study of smoking at diagnosis and 
survival in colon cancer - current smokers (but not ex-smokers) had a statistically significant, 14% 
higher, rate of cancer death compared to never smokers.  
Although all of the eight previous studies of colon cancer patients reported poorer survival (by at 
least by one measure cancer-specific, disease-free or recurrence-free survival) in smokers than non- 
or never smokers,7,13-16,37-39  the association was not statistically significant in four studies and, in one 
further study, there was a significant reduction in disease-free survival but not in cancer-specific 
survival. In part this is likely to be due to the relatively modest sample size and hence limited 
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statistical power of most of the studies. In the studies which reported significant findings, the hazard 
ratio for current smokers was around 1.5.7,15,16,39 One reason for the more modest association in the 
current study than these studies may that our data was from a population-based cancer registry; the 
analysis therefore included all (or, at least 97% of)22 colon adenocarcinomas diagnosed in Ireland 
during 1994-2012 eliminating any possibility of selection or participation biases. Of the previous 
studies, none was truly population-based; three of the eight studies sampled potential participants 
(who could then agree or decline to participate) from a population-based sampling frame13,15,37  and, 
of these, only one reported a significant increased hazard for smokers.15  Another possible 
explanation for the more modest association in our study is that we adjusted for deprivation.  
Deprivation is a marker of socio-economic status and past studies have reported positive 
associations between various markers of socio-economic status and colon cancer survival.40-42 
Smoking prevalence tends to be higher in people of lower socio-economic status and/or in more 
deprived areas,43 and this is also seen in Ireland.44  Thus, adjustment for deprivation would be likely 
to attenuate observed associations between smoking and survival. 
The observed interaction between smoking and treatment, such that the adverse effect of current 
smoking was limited to patients who had cancer-directed surgery only, is noteworthy. Several 
studies have convincingly shown more post-operative complications and higher post-operative 
mortality in colon (or colorectal) cancer patients who smoke.18,19 However, these studies mainly 
considered short-term outcomes (e.g. 30-day mortality). The current study therefore adds to the 
evidence-base by showing that smoking adversely affects 5-year survival in surgically-treated 
patients.  Moreover, the landmark analysis, which included patients who had survived 6 months, 
suggests that the adverse effect of smoking is not limited to the period immediately post-surgery but 
extends longer-term.  In addition, our results confirm – in a much larger series and at the 
population-level - the findings of Munro et al20 who reported that active smokers (but not ex-
smokers) had a significantly increased hazard compared to non-smokers; and extend these to show 
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that there is no adverse effect of smoking in non-surgical patients. The consistent results in the 
landmark analysis indicate our results are not due to immortal time bias.45 Our findings, and those of 
Munro et al,20 suggest that the mechanism(s) by which smoking impacts on colon cancer survival are 
related, in some way, to surgery. 
The lack of association between smoking and survival in surgical patients who also had 
chemotherapy is intriguing. It seems likely that those who receive chemotherapy are fitter, 
suggesting that the effect of smoking may be stronger (or only evident) in less fit patients. This might 
usefully be investigated in future studies. 
A significant proportion of colon cancers presents as emergencies and require rapid surgical 
intervention.46,47 A Swedish study found that colon cancer patients with a lower level of education, 
or lower income, were more likely to present as emergencies48 and, in analyses of a subgroup of 
colon cancers in Ireland, 31% of current smokers presented as emergencies compared to 24% of ex-
smokers and never smokers combined.  Since cases which present as emergencies have higher 
mortality,46,49 this suggests that a higher frequency of emergency presentation among smokers could 
help explain the observed association.   Positive margins are a risk factor for recurrence following 
resection for colon cancer17 and a single study has reported a slightly higher rate of radial margin 
positivity among current smokers (6.4%) than other colon cancer patients (5.1%).50 However, the 
overall rate of radial margin positivity appears too low to fully explain the survival differential 
between current and never smokers. Another possible explanation follows from the observations 
that smoking induces a systemic inflammatory response51 and that systemic inflammatory response 
is a prognostic factor following colorectal resection.52 Finally, smoking may be a marker for raised 
levels of the complex glycoprotein carcinoembryonic antigen (CEA), which is a strong prognostic 
factor in colorectal cancer.53 Studies among apparently healthy volunteers have found associations 
between smoking and higher CEA levels.54,55 Further investigations of these potential mechanisms 
would be of considerable value. 
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Like a few previous studies,38,51 we found that current smokers were more often diagnosed with 
more advanced disease.  While this might point to a tumour promoting effect of smoking, it may also 
be due to different patterns of healthcare consultation in smokers and non-smokers. Further 
research to better understand this relationship might illuminate the mechanisms by which smoking 
influences cancer progression.  
Strengths and limitations 
Although our data was population-based, the fact that it was derived from a cancer registry meant 
that we did not have information on disease free survival, nor did we have any information on 
tobacco exposure other than smoking status at diagnosis. We also lacked information on other 
lifestyle factors some of which have been related to colon cancer survival and may be associated 
with smoking. Smoking status was derived from medical records and, as such, may be subject to 
misclassification. Data suggests that, in face-to-face interviews for research studies, few people in 
the general population misrepresent their use of tobacco products,57 but whether this holds for 
cancer patients in discussions with health professionals who are involved in their treatment is less 
certain.  It seems most likely that – due to social desirability bias- any misclassification will be 
differential, such that current smokers are more likely to have been classified as non-smokers than 
vice versa; this would mean that the hazard ratios are biased towards the null and we have 
underestimated the true association between smoking and survival. We chose to base our analysis 
on cancer-specific survival rather than overall survival because the latter is likely influenced by the 
impact of smoking on other major causes of death, notably cardiovascular disease.  Cancer-specific 
survival analyses are reliant on accurate information on cause of death. While it is well recognised 
that the cause of death recorded on some death certificates is inaccurate,58 there does not appear to 
be any published data to suggest that (in)accuracy is differential by smoking status. In addition, while 
the SEER classification of cancer-specific deaths includes cancers at sites outside the body system of 
interest,23 and in our study there were some deaths at sites other than the bowel, numbers were 
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small (~2% of deaths). Almost half were coded to the lung or liver so probably represent metastases 
from the primary tumour; others may represent cancers diagnosed before 1994, about which we 
had no information. Moreover, the rate of non-cancer deaths was higher among current smokers 
and ex-smokers than never smokers in our dataset, providing some reassurance about the accuracy 
of death certificates and suggesting that the poorer survival observed in smokers is unlikely to be 
due to non-cancer deaths being mis-coded as cancer deaths.  
Implications 
Although not specific to colon cancer, evidence suggests that some cancer patients give up smoking 
around the time of diagnosis and others want to stop,59-60 and that smoking cessation interventions 
can be successful among patients/survivors.61,62  A single trial of a smoking cessation intervention in 
patients undergoing colorectal resection found no difference in post-operative complication rates 
between arms,63 but the sample size was small (n=60).  Further studies are needed to investigate 
whether smoking cessation around the time of diagnosis improves patients’ outcomes, either in the 
short or longer-term. 
Conclusions 
In this large, population-based, cohort study of newly diagnosed colon cancer patients, current 
smokers (but not ex-smokers) had a significantly increased rate of cancer death compared to never 
smokers. This effect was limited to those patients who had cancer-directed surgery, suggesting that 
the mechanism by which smoking impacts on survival is in some way related to surgery. Further 
research is needed to better elucidate these mechanisms but, meanwhile, continued efforts to 
encourage smoking prevention and cessation may bring benefits in terms of improved survival from 
colon cancer. 
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STROBE Statement—checklist of items that should be included in reports of observational studies 
 
 Item 
No 
Recommendation 
Details and/or 
location in manuscript 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract Title contains description of design – 
“population-based cohort”; also included in 
abstract 
(b) Provide in the abstract an informative and balanced summary of what was done and what 
was found 
Abstract describes methods and results 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported Review and critique of the past literature 
included in the Introduction (page 3-4) 
Objectives 3 State specific objectives, including any prespecified hypotheses Objectives described at end of Introduction 
(page 4) 
Methods  
Study design 4 Present key elements of study design early in the paper Design stated in final paragraph of 
Introduction (page 4) 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, 
exposure, follow-up, and data collection 
Setting, population, sources of data, exposure 
and follow-up described in Methods (pages 
4-5) 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of 
participants. Describe methods of follow-up 
Case-control study—Give the eligibility criteria, and the sources and methods of case 
ascertainment and control selection. Give the rationale for the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection 
of participants 
Eligibility criteria for inclusion in study 
population described on page 4; sources of 
participants described on page 4; follow-up 
described on pages 4 and 5 
(b) Cohort study—For matched studies, give matching criteria and number of exposed and 
unexposed 
Case-control study—For matched studies, give matching criteria and the number of controls 
Design not matched 
23 
 
per case 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable 
Outcomes (definition of cancer and other 
deaths) described on page 5. Predictor 
(smoking) described on page 5. Potential 
confounders (socio-demographic and clinical 
characteristics) described on page 5. 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one 
group 
Source and classification of variables of 
interest described n page 4 and 5. 
Bias 9 Describe any efforts to address potential sources of bias Multiple imputation used to fill missing 
values in smoking status and key 
confounders – described on page 6. Done to 
deal with potential bias of complete case 
analysis. Full details provided in supporting 
table 1. 
Study size 10 Explain how the study size was arrived at All primary colon adenocarcinomas 
registered in Ireland included; described on 
page 4 
Quantitative 
variables 
11 Explain how quantitative variables were handled in the analyses. If applicable, describe 
which groupings were chosen and why 
Classification of quantitative variables 
included on page 5 and table 1. 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding Full details of statistical analysis included on 
page 6 and 7. 
(b) Describe any methods used to examine subgroups and interactions Subgroup and interaction analysis (by 
treatment receipt) included on pages 6 & 7 
(c) Explain how missing data were addressed Multiple imputation methods described on 
page 6 
(d) Cohort study—If applicable, explain how loss to follow-up was addressed 
Case-control study—If applicable, explain how matching of cases and controls was 
addressed 
Deaths ascertained by linkage with national 
death records so loss to follow-up not a 
significant consideration. 
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Cross-sectional study—If applicable, describe analytical methods taking account of sampling 
strategy 
(e) Describe any sensitivity analyses Sensitivity analyses (complete case) 
described on page 7, results reported on page 
9 and in supporting tables 
Continued on next page
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Results  
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined 
for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed 
Numbers of cases excluded – and reasons 
for this - described in methods (page 4); 
numbers included in primary and 
sensitivity analyses described in methods 
and tables 1-3 and supporting tables 2-4 
(b) Give reasons for non-participation at each stage Reasons for exclusions reported on page 
4. 
(c) Consider use of a flow diagram Definition of cohort straightforward so 
flow diagram not provided 
Descriptive 
data 
14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on 
exposures and potential confounders 
Provided in table 1 (and supporting table 
2) 
(b) Indicate number of participants with missing data for each variable of interest Information provided in the methods 
(pages 4-7) 
(c) Cohort study—Summarise follow-up time (eg, average and total amount) Cases followed-up for 5 years or to death; 
described in methods 
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time Numbers of deaths reported in Table 2 
Case-control study—Report numbers in each exposure category, or summary measures of exposure  
Cross-sectional study—Report numbers of outcome events or summary measures  
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 
95% confidence interval). Make clear which confounders were adjusted for and why they were 
included 
Unadjusted and adjusted estimates 
reported in tables 2 & 3; rationale for 
adjustments described on pages 6 & 7 
(b) Report category boundaries when continuous variables were categorized Categorises reported in Tables 1 & 2  
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time 
period 
Results reported as hazard ratios 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Subgroup analyses reported in Table 3; 
sensitivity analyses reported in supporting 
tables 2-4 
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Discussion  
Key results 18 Summarise key results with reference to study objectives Results summarised and discussed pages 
9-12 and repeated in conclusion (pages 
12-13) 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss 
both direction and magnitude of any potential bias 
Limitations discussed on page 12 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other relevant evidence 
Results interpreted in the context of 
previous findings on pages 9-11 
Generalisability 21 Discuss the generalisability (external validity) of the study results Generalisability discussed on page 10 
(with reference to population-based nature 
of study) 
Other information  
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the 
original study on which the present article is based 
Information on funders provided in the 
Statement of Interests 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The 
STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal 
Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org. 
 
 
 
 
